All In Biotech

Drug Trial Radar · NCT03052725

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Last checked: Nov 20, 2026Latest source record: Dec 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

391

Actual

Start

Mar 10, 2017

Primary completion

Feb 22, 2018

Study completion Feb 22, 2018

Sponsor

Sponsor type
Industry
First posted
Feb 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.

Conditions

  • Eosinophils, Asthma

Interventions

  • reslizumabDrug

    Reslizumab was provided in a pre-filled syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 to up to Day 269; for participants who discontinued early for reasons other than study termination, the timeframe was first dose of study drug to 4 weeks after the last dose of study drug.

Locations

134 sites in 13 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 14647

    Birmingham, Alabama

  • Teva Investigational Site 14631

    Bakersfield, California

  • Teva Investigational Site 14648

    Huntington Beach, California

  • Teva Investigational Site 14637

    Napa, California

  • Teva Investigational Site 14654

    Stockton, California

  • Teva Investigational Site 14636

    Walnut Creek, California

  • Teva Investigational Site 14626

    Aventura, Florida

  • Teva Investigational Site 14634

    Homestead, Florida

  • Teva Investigational Site 14650

    Miami, Florida

  • Teva Investigational Site 14629

    Miami, Florida

  • Teva Investigational Site 14619

    Miami, Florida

  • Teva Investigational Site 14624

    Orlando, Florida

  • Teva Investigational Site 14638

    Tallahassee, Florida

  • Teva Investigational Site 14642

    Buford, Georgia

  • Teva Investigational Site 14651

    Chicago, Illinois

  • Teva Investigational Site 14645

    Michigan City, Indiana

  • Teva Investigational Site 14620

    Owensboro, Kentucky

  • Teva Investigational Site 14623

    Lafayette, Louisiana

  • Teva Investigational Site 14627

    North Dartmouth, Massachusetts

  • Teva Investigational Site 14644

    Boys Town, Nebraska

  • Teva Investigational Site 14652

    Ocean City, New Jersey

  • Teva Investigational Site 14632

    Lake Success, New York

  • Teva Investigational Site 14646

    New York, New York

  • Teva Investigational Site 14633

    Cincinnati, Ohio

  • Teva Investigational Site 14653

    Cleveland, Ohio

  • Teva Investigational Site 14621

    Edmond, Oklahoma

  • Teva Investigational Site 14625

    Edmond, Oklahoma

  • Teva Investigational Site 14643

    Jenkintown, Pennsylvania

  • Teva Investigational Site 14622

    Pittsburgh, Pennsylvania

  • Teva Investigational Site 14630

    East Providence, Rhode Island

  • Teva Investigational Site 14649

    Providence, Rhode Island

  • Teva Investigational Site 14655

    Knoxville, Tennessee

  • Teva Investigational Site 14639

    Corsicana, Texas

  • Teva Investigational Site 14640

    Dallas, Texas

  • Teva Investigational Site 14641

    Provo, Utah

  • Teva Investigational Site 14628

    Abingdon, Virginia

  • Teva Investigational Site 14635

    Falls Church, Virginia

  • Teva Investigational Site 37082

    Brussels, Belgium

  • Teva Investigational Site 37081

    Erpent, Belgium

  • Teva Investigational Site 37083

    Ghent, Belgium

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.